Huddersfield Pharmacy Specials (HPS) is delighted to announce that the business has been selected to formulate and manufacture active and placebo medicines for a pragmatic, multicentre, randomised controlled trial of active versus placebo in patients clinically at high-risk of developing psychosis.

HPS will be responsible for and advising upon the investigational medicinal product dossier (IMPD), investigative brochure (IB) and clinical trial application (CTA). Allied to these functions, HPS will lead on IMP and placebo development, manufacturing, packaging and finally subsequent distribution to trial sites.